Login to Your Account

Clinic Roundup

Wednesday, August 15, 2012
• Soricimed Biopharma Inc., of Toronto, initiated the Phase I trial of its anticancer agent SOR-C13. The multicenter, open-label, dose-escalation study is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription